Pharmacovigilance – Products

ScreenIn3D reports on how their proprietary lab-on-a-chip technology is enabling cancer researchers to miniaturize their testing of biopsy tissue samples across a wide range of modalities and to test both single and combination drug therapies.

RemeGen Co., Ltd. announced that their Phase II clinical study of telitacicept for the treatment of Primary Sjögren's Syndromein adults has been published.

Sapient has been awarded accreditation from the College of American Pathologists (CAP).

InSphero AG and Cosmo Bio Co., Ltd. are announcing a strategic partnership to distribute InSphero’s innovative product portfolio in Japan.

TVM Capital Life Science, together with specialty pharma company, Tillotts Pharma has announced that the companies will jointly invest up to USD 28 million in the newly formed U.S.-based biotechnology company, Mage Biologics Inc.

A landmark study demonstrates that precision oncology medicines could deliver a superior return on Investment for Pharma R&D vs their one size fits all counterparts.

Thermo Fisher Scientific has announced the launch of the first commercially available culture medium specifically developed for the expansion of patient-derived cancer organoids, from multiple cancer indications.

Sygnature Discovery has established an in vivo LPS model of inflammation which can help understand life-limiting neuroinflammatory conditions like Parkinson’s disease, multiple sclerosis, Alzheimer’s disease, and traumatic brain injuries and identify new drug targets.

Avacta Group plc has announced that the fifth dose escalation cohort in the ALS-6000-101 dose escalation Phase 1 clinical trial to evaluate the safety and tolerability of AVA6000 has been completed successfully.

This application note outlines the importance of reagent consistency in organoid tissue culture.